Palvella completes NDA submission for QTORIN rapamycin gel in rare LM

Palvella Therapeutics has completed a rolling New Drug Application submission to the FDA for QTORIN 3.9% rapamycin anhydrous gel as a treatment for microcystic lymphatic malformations (microcystic LMs), a rare genetic condition characterised by abnormal lymphatic vessel growth in soft tissue. The Wayne, Pennsylvania-based company said the application positions QTORIN rapamycin as a potential first approved therapy for an estimated 30,000 paediatric and adult patients in the United States.

The NDA was submitted via the 505(b)(2) regulatory pathway, which permits the FDA to draw on prior safety and efficacy findings and existing published data, potentially streamlining the agency's review. Palvella said the FDA must determine within 60 days whether the application is complete and eligible for filing, and whether Priority Review will be granted. A Priority Review designation would shorten the standard review clock to six months from the standard ten to twelve months.

Trial data underpinning the application

The submission is anchored by results from the Phase 3 SELVA trial, which the company reported met its primary endpoint and all four pre-specified secondary efficacy endpoints, with statistical significance across all six measures (p less than 0.001 in each case). Among participants aged six years and older who completed the 24-week efficacy evaluation, 86% were rated "Much Improved" or "Very Much Improved" on the Microcystic Lymphatic Malformation Investigator Global Assessment, the study's primary instrument. On safety, no drug-related serious adverse events were reported, and systemic rapamycin levels remained below 2 ng/mL at all timepoints, a meaningful finding given that systemic rapamycin is associated with immunosuppression and metabolic side-effects at therapeutic concentrations used in transplant medicine.

The NDA also incorporates Phase 2 data that previously supported the FDA's decision to grant Breakthrough Therapy designation, alongside published literature on off-label rapamycin use in microcystic LMs. QTORIN rapamycin additionally holds Fast Track and Orphan Drug designations, the latter of which, if approval follows, would confer seven years of US market exclusivity.

Wes Kaupinen, founder and chief executive of Palvella, said completing the NDA brought the company "one step closer to our goal of delivering the first FDA-approved therapy for patients living with microcystic LMs."

Regulatory context and competitive landscape

Microcystic LMs represent an archetypal rare vascular anomaly: a condition managed largely through interventional radiology, sclerotherapy, and surgery, with no systemic pharmaceutical standard of care. The mTOR pathway, which rapamycin inhibits, has attracted growing interest in vascular anomaly research over the past decade, with several academic groups and companies exploring topical and systemic formulations. Palvella's topical gel formulation is designed to deliver local mTOR inhibition while limiting systemic exposure, addressing a key tolerability concern that has constrained oral rapamycin use in paediatric populations.

Should Priority Review be granted, a potential PDUFA-date decision could fall in early 2027, broadly consistent with Palvella's stated target of a first-half 2027 commercial launch. The company said it has already deployed a field-based medical science liaison network and established a patient services organisation in anticipation of approval. Investors will be watching the FDA's 60-day filing acceptance decision as the first near-term catalyst, followed by any Priority Review determination.